source
- Longeveron’s pediatric heart stem-cell trial misses primary endpoint, prompting cost cutsLongeveron reported that its phase 2b Elpis II trial of the stem-cell product laromestrocel in infants with hypoplastic left heart syndrome failed to meet its primary efficacy endpoint. The study…
- CMS launches 10-year ACCESS health-tech pilot for MedicareCMS recently held an event to commemorate the summer launch of the ACCESS model, a decade-long pilot aimed at integrating health-technology solutions into Medicare. The program will test new digit…